Colorectal cancer liver metastases: Biopsy of the ablation zone and margins can be used to predict oncologic outcome

Radiology

Volumn 280, Issue 3, 2016, Pages 949-959

  Sotirchos, Vlasios S ^a   Petrovic, Lydia M ^a,e,f   Gönen, Mithat ^b   Klimstra, David S ^c   Do, Richard K G ^c   Petre, Elena N ^a   Garcia, Alessandra R ^c   Barlas, Afsar ^d   Erinjeri, Joseph P ^a   Brown, Karen T ^a   Covey, Anne M ^a   Alago, William ^a   Brody, Lynn A ^a   DeMatteo, Ronald P ^c   Kemeny, Nancy E ^c   Solomon, Stephen B ^a   Manova Todorova, Katia O ^d   Sofocleous, Constantinos T ^a  

^a Department of Radiology Section of Interventional Radiology   (United States)

^b Departments of Epidemiology and Biostatistics   (United States)

^c Department of Pathology ^*  (United States)

^d Molecular Cytology   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f USC UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER SIZE; CENTRAL ABLATION ZONE; CLINICAL ARTICLE; COIL EMBOLIZATION; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DYSPNEA; FALSE ANEURYSM; FEMALE; FEVER; FOLLOW UP; HEPATIC ARTERY PSEUDOANEURYSM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSTITUTIONAL REVIEW; LIVER HEMATOMA; LUNG EMBOLISM; MALE; MARGINAL ABLATION ZONE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; SURVIVAL TIME; THORACOSTOMY; THROMBOCYTOPENIA; TIME TO LOCAL TUMOR PROGRESSION; TUMOR BIOPSY; TUMOR NECROSIS; BIOPSY; CATHETER ABLATION; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; DISEASE COURSE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOFREQUENCY RADIATION; SECONDARY; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CATHETER ABLATION; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RADIO WAVES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84986236305     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016151005     Document Type: Article

References (41)

1. Hanna NN. Radiofrequency ablation of primary and metastatic hepatic malignancies. Clin Colorectal Cancer 2004;4(2):92-100.
2. Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 2011;10(4):258-265.
3. Adam R, Vinet E. Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol 2004;15(Suppl 4):iv103-iv106.
4. Curley SA, Izzo F. Radiofrequency ablation of primary and metastatic liver tumors. Surg Technol Int 2002;10:99-106.
5. Chen MH, Yang W, Yan K, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005;11(40):6395-6401.
6. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007;189(4):883-889.
7. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005;235(3):728-739.
8. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma carafter occlusion of tumor blood supply. Radiology 2000;217(1):119-126.
9. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221(1):159-166.
10. White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 2007;11(3):256-263.
11. Sofocleous CT, Klein KM, Hubbi B, et al. Histopathologic evaluation of tissue extracted on the radiofrequency probe after ablation of liver tumors: preliminary findings. AJR Am J Roentgenol 2004;183(1):209-213.
12. Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology 2008; 249(1):364-374.
13. Sofocleous CT, Garg S, Petrovic LM, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol 2012;19(13):4262-4269.
14. Sofocleous CT, Garg SK, Cohen P, et al. Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation. Ann Surg Oncol 2013;20(Suppl 3):S676-S683.
15. Snoeren N, Jansen MC, Rijken AM, et al. Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours. Dig Surg 2009;26(1):56-62.
16. Snoeren N, Huiskens J, Rijken AM, et al. Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression. Ann Surg Oncol 2011;18(13):3702-3710.
17. Ryan ER, Sofocleous CT, Schöder H, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013;268(1):288-295.
18. Saldanha DF, Khiatani VL, Carrillo TC, et al. Current tumor ablation technologies: basic science and device review. Semin Intervent Radiol 2010;27(3):247-254.
19. Sofocleous CT, Sideras P, Petre EN. How we do it: a practical approach to hepatic metastases ablation techniques. Tech Vasc Interv Radiol 2013;16(4):219-229.
20. Weber JC, Nakano H, Bachellier P, et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 2001;182(1):81-88.
21. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182(3):311-322.
22. Fujisawa S, Romin Y, Barlas A, et al. Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology 2014;66(2):259-273.
23. Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013;36(1):166-175.
24. Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology 2014;273(1):241-260.
25. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010;33(1):11-17.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94(446):496-509.
27. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Sec 8.2.3. New York, NY: Wiley, 2002.
28. Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 2007;246(2):295-300.
29. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25(29):4575-4580.
30. Tranchart H, Chirica M, Faron M, et al. Prognostic impact of positive surgical margins after resection of colorectal cancer liver metastases: reappraisal in the era of modern chemotherapy. World J Surg 2013;37(11):2647-2654.
31. Andreou A, Aloia TA, Brouquet A, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013;257(6):1079-1088.
32. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (. 2 and , 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 2010;195(3):758-765.
33. Liu CH, Arellano RS, Uppot RN, Samir AE, Gervais DA, Mueller PR. Radiofrequency ablation of hepatic tumours: effect of postablation margin on local tumour progression. Eur Radiol 2010;20(4):877-885.
34. Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007;188(2):480-488.
35. Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes-a 10-year experience at a single center. Radiology 2016;278(2):601-611.
36. Meloni MF, Andreano A, Zimbaro F, Lava M, Lazzaroni S, Sironi S. Contrast enhanced ultrasound: roles in immediate post-procedural and 24-h evaluation of the effectiveness of thermal ablation of liver tumors. J Ultrasound 2012;15(4):207-214.
37. Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 2008;67(2):362-371.
38. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88(11):2452-2463.
39. Morimoto M, Sugimori K, Shirato K, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologichistologic correlation during follow-up periods. Hepatology 2002;35(6):1467-1475.
40. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241(5):715-722; discussion 722-724.
41. Muratore A, Ribero D, Zimmitti G, Mellano A, Langella S, Capussotti L. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol 2010;17(5):1324-1329.